TITLE

Simultaneous occurrence of two B-cell malignancies: A case report

AUTHOR(S)
SHUJUAN ZHOU; YONGYONG MA; LAIXI BI; ZHIJIAN SHEN; KANG YU
PUB. DATE
August 2014
SOURCE
Oncology Letters;2014, Vol. 8 Issue 2, p908
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
The present study describes the case of a 75-year-old male with coexisting multiple myeloma and diffuse large B-cell lymphoma. Although the two malignancies are mature B-cell neoplasms, their clinical manifestations are very different and the clinical approaches used to treat these two types of tumor vary. The patient in the present case was diagnosed with the simultaneous existence of two different B-cell tumors and was successfully treated using the DCEP regimen. The simultaneous presentation of two mature B-cell neoplasms, types of hematological malignancy, is very rare, thus the present case is considered to be interesting.
ACCESSION #
110397836

 

Related Articles

  • Idelalisib approved for three blood cancers. Traynor, Kate // American Journal of Health-System Pharmacy;9/1/2014, Vol. 71 Issue 17, p1430 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of idelalisib oral tablets for blood cancer on July 23, 2014. Topics covered include the types of blood cancer indicated in the labeling for the drug, the approval made via the breakthrough therapy program of FDA...

  • The lighter side of myeloma: an easily overlooked diagnosis. Spiller, Robin; Feld, J. J.; Guindi, M.; Heathcote, E. J. // Gut;Oct2005, Vol. 54 Issue 10, p1376 

    Presents case report of a 61 year old man who developed back pain, fatigue, and anaemia. Treatment of the patient; Information that IgG K multiple myeloma was diagnosed and the patient was treated with vincristine, adriamycm, and dexamethasone; Questions related to the diagnosis.

  • Doxorubicin liposomal.  // Reactions Weekly;9/18/2004, Issue 1019, p9 

    Discusses research being done on the side effects of antineoplastic therapy with doxorubicin liposomal in an elderly patient with multiple myeloma. Reference to a study by P. Kiewe and colleagues published in the July to August 2004 issue of "Annals of Pharmacotherapy"; Occurrence of ageusia;...

  • High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Gojo, I.; Guo, C.; Sarkodee-adoo, C.; Meisenberg, B.; Fassas, A.; Rapoport, A.; Cottler-fox, M.; Heyman, M.; Takebe, N.; Tricot, G. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p69 

    Summary:The purpose of the study was to examine the yield of CD34+ cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5?g/m2 (n=28) alone or with etoposide...

  • The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Braga, Walter M. T.; Atanackovic, Djordje; Colleoni, GiseleW. B. // Clinical & Developmental Immunology;2012, p1 

    The development of multiple myeloma (MM) involves a series of genetic alterations and changes in the bone marrow microenvironment, favoring the growth of the tumor and failure of local immune control. Quantitative and functional alterations in CD4+ and CD8+ T cells have been described in MM. The...

  • Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Kumar, S.; Lacy, M. Q.; Dispenzieri, A.; Rajkumar, S. V.; Fonseca, R.; Geyer, S.; Allmer, C.; Witzig, T. E.; Lust, J. A.; Greipp, P. R.; Kyle, R. A.; Litzow, M. R.; Gertz, M. A. // Bone Marrow Transplantation;Sep2004, Vol. 34 Issue 6, p485 

    Summary:Given the survival advantage, high-dose therapy (HDT) remains the standard of care for patients with multiple myeloma eligible for the procedure. For those undergoing HDT, initial therapy aimed at reducing tumor burden is given prior to stem cell harvest. Various regimens, mostly...

  • High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Stessman, H A F; Lulla, A; Xia, T; Mitra, A; Harding, T; Mansoor, A; Myers, C L; Van Ness, B G; Dolloff, N G // Leukemia (08876924);Nov2014, Vol. 28 Issue 11, p2263 

    The article presents a study which develops a high-throughput drug screening (HTS) platform to determine chemical structures that selectively kill or re-sensitize PI-resistant multiple myeloma (MM) cells to proteasome inhibitors (PIs). It states that a cell-based drug screening assay was...

  • Bortezomib.  // Reactions Weekly;10/4/2008, Issue 1222, p10 

    The article describes the case of a 69-year-old man who acquired neuropathic pain. The patient, who has multiple myeloma, developed the said condition while using bortezomib as third-line chemotherapy because of high paraprotein levels. The patient had previously taken other antineoplastic...

  • Biological Activity of Lenalidomide and Its Underlying Therapeutic Effects in Multiple Myeloma. Martiniani, Roberta; Di Loreto, Valentina; Di Sano, Chiara; Lombardo, Alessandra; Liberati, Anna Marina // Advances in Hematology;2012, p1 

    Lenalidomide is a synthetic compound derived by modifying the chemical structure of thalidomide. It belongs to the second generation of immunomodulatory drugs (IMiDs) and possesses pleiotropic properties. Even if lenalidomide has been shown to be active in the treatment of several hematologic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics